Australia approves first-in-class Niktimvo for later-line cGVHD

RegulatoryapprovedNiktimvoPositive

AI Analysis

Summary

Specialised Therapeutics' Niktimvo (axatilimab), a first-in-class therapy, has been approved by Australian authorities for the treatment of later-line chronic graft-versus-host disease.

Outcome Details

Registered in Australian Register of Therapeutic Goods

Importance:6/10

Sentiment:

0.80

regulatory approvalAustraliafirst-in-classcGVHDaxatilimab

Related Companies

$TRAX

Read the original article

Published by Pharmaceutical Technology on July 30, 2026 2:07 PM

Read Original